BridgeMD
New treatment option for Lung Non-Small Cell Carcinoma
Official title Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
ClinicalTrials.gov ID: NCT06139627
What this study is testing
- What it's testing
- This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical consequences.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older. Healthy volunteers may be eligible.
You may be able to join if
- ONCOLOGY PHYSICIANS INCLUSION:
- Oncology physicians must work at the participating site with no plans to leave that site or retire at the time of enrollment into the study
- PATIENTS INCLUSION:
- Any patient with unresectable non-small cell lung cancer diagnosis who is 60 years of age or older and must be treated at the participating site
- Clinical staging without pathological confirmation of nodal disease is allowed
You likely can't join if
- are met
- Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated...
- Participant or healthcare proxy has adequate understanding of the English language (preferred) because not all GA measures have been validated in...
- PATIENTS EXCLUSION:
- Have surgery planned within 3 months of approach date. Patients who have previously received surgery are eligible
- Presence of symptomatic brain metastases (if more than one) at time of study consent process. Patients with history of treated brain metastases or...
See the full eligibility criteria
- ONCOLOGY PHYSICIANS INCLUSION:
- Oncology physicians must work at the participating site with no plans to leave that site or retire at the time of enrollment into the study
- PATIENTS INCLUSION:
- Any patient with unresectable non-small cell lung cancer diagnosis who is 60 years of age or older and must be treated at the participating site
- Clinical staging without pathological confirmation of nodal disease is allowed
- Plan to start a new cancer treatment regimen within 4-6 weeks from time of baseline study visit. The treatment regimen is up to the discretion of the treating oncology physician. The regimen must include a chemotherapy...
- Chemotherapy will be defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) will be allowed. Given the rapidly changing landscape of new drugs for cancer, the study team led by...
- Patients who are receiving approved cancer treatment in combination or sequentially with radiation including hypo fractionated radiation (45-60Gy in 15-20 fractions) are eligible
- Those patients with oligometastatic disease having only one site and one lesion outside of the radiation field will be eligible. Examples include a solitary brain metastasis (met), contralateral lung nodule or an...
- A patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and
- are met
- Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional...
- Participant or healthcare proxy has adequate understanding of the English language (preferred) because not all GA measures have been validated in other languages. Study team should be contacted for any participants with...
- PATIENTS EXCLUSION:
- Have surgery planned within 3 months of approach date. Patients who have previously received surgery are eligible
- Presence of symptomatic brain metastases (if more than one) at time of study consent process. Patients with history of treated brain metastases or small indeterminate lesions (\< 1cm) are eligible if they are not...
- More than one metastatic site: Examples: brain and adrenal, adrenal and liver
The study team makes the final eligibility decision.
Where it's taking place
- Duarte, California, United States
- Rochester, New York, United States
- Columbus, Ohio, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Duarte, California, United States; Rochester, New York, United States; Columbus, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.